Hilary Rosselot
Hilary joined the NFXF team in 2019. Prior to joining the NFXF team, she worked at the Cincinnati Fragile X Research and Treatment Center for several years. She has experience as a clinical research coordinator across many types of clinical trials and served as the clinical research manager for the Cincinnati program. She earned a bachelor’s in psychology, an MBA, and was previously a SOCRA-certified clinical research professional (CCRP). She enjoys spending time with her family, including her young daughter and Boston Terrier, as well as curling up with a good book.
More from the Author
We know many individuals living with Fragile X want to work, and though some do, not everyone who wants a job has found one that best fits their strengths and skill sets. We’re determined to help you educate yourself on the existing supports and how to best advocate in the workplace.
The initiative will build on our 40 years of work, promoting broader use of evidence-based information among individuals with FXS, caregivers, family members, community partners, and healthcare providers nationwide.
Our 2026 NFXF awards are in! Learn more about each award and the respective awardees.
Reach out to your Members of Congress and stress the critical importance of continued federal support, including NIH funding for Fragile X research.
We are excited to share that three fantastic new board members are joining the National Fragile X Foundation this year. Join us in welcoming Jill Dolan, Michele Kaplan, and Kerry Stedke to the NFXF Board of Directors.
We are seeing numerous proposed changes this Congress that would have a significant impact on the Fragile X community. It’s more important than ever that your members of Congress hear directly from you — your voice matters.
NFXF Executive Director Hilary Rosselot and Advocacy Ambassador to the NFXF Board of Directors Dillon Kelley attended the CEO Commission for Disability Employment’s Employment Summit and Hill Day in September. It was an inspiring, action-packed few days, and they are excited to share more about their experience and why it matters to the Fragile X community with you.
Meet the 2024 NFXF Summer Scholars, Emily Peery, Thomas Christensen, Emily Timm, and Manasi Inamdar, and see their winning presentations.
Use our customizable “About Me” template to help describe Fragile X to your schoolmates or colleagues.
Our 2024 NFXF awards are in! Learn more about each award and the respective awardees.
Nearly 60 doctors, clinic coordinators, and others from 20 of the 32 FXCRC clinics met at the Children’s Hospital outside Denver.
We are proud to be part of the Everylife Foundation’s newest report, which uses real-world data to evaluate healthcare usage in seven rare diseases and its relationship to timely diagnosis and the diagnostic odyssey.
See 2023’s three NFXF Summer Scholars, Aditi Mahajan, Alexandra Singleton, and Maureen Butler,! summarize their summer project in a video presentation.
PureTech Health has been awarded a grant from the DOD for their trial of LYT-300, oral formulation of allopregnanolone, in people with FXTAS.
Red tape should never stand between a child and their treatment. But sometimes, they face burdensome, unnecessary challenges when getting care in another state.
More research is needed to better understand the progression of FMRP expression across the lifespan and how FMRP is related to all aspects of functioning.
With the establishment of the FXTAS diagnostic criteria and the successful management of the symptoms of this disease, the next steps are focused on finding a cure or reducing the FXTAS progression.
A publication was released summarizing one lab’s discovery that could lead to a future treatment for Fragile X.
Allos Pharma announced they held a meeting with the FDA to optimize the design of their Phase 3 trial designed to support an NDA to address FXS.
Research is needed that includes more racially and ethnically diverse participants. This study relied on self-reports to measure cognition.
Fragile X conditions can be complicated to explain. Here we provide seven basic facts about the biology and genetics of Fragile X to help with understanding.
Congratulations to 2022’s five NFXF Summer Scholars — Andy King, Natalia Rivera Alfaro, Dominic DeBiasi, Jordan Norris, and Jessica Tang!
We are sharing information on a 2023 funding opportunity from CDMRP and PRMRP.
Healx shares the closing of their IMPACT-FXS trial with plans to open a new study in early 2023.
The American Academy of Pediatrics (AAP), with support from the CDC, hosted “Identification, Management, Caring for Children with Fragile X Syndrome Virtual Course” on June 22, 2022. The course will be available as a free AAP course through August 1, 2025.
FMR1 now stands for fragile X messenger ribonucleoprotein 1, removing the reference to “mental retardation” which has long been outdated in common vernacular. At the time of discovery, “mental retardation” was an accepted term for what we now call “intellectual disability.”
Dr. Liz Berry-Kravis and Tetra Therapeutics published the BPN14770 trial results in Nature Medicine on April 29, 2021. We present a summary of those research results.
Understanding screening issues and challenges is crucial to advancing the Fragile X field as it relates to diagnosis and treatment.